Foghorn Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Foghorn Therapeutics Inc. (FHTX) on January 12, 2026, covering events occurring on January 9, 2026. The filing announces a completed private placement of equity securities and the release of preliminary financial information as of December 31, 2025, ahead of the 44th Annual J.P. Morgan Healthcare Conference.
Key Financial Metrics and Capital Raise
The Company executed a capital raise with the following terms:
- Gross Proceeds: Approximately $50.0 million.
- Offering Price: $6.71 per share of Common Stock (or $6.7099 per Pre-Funded Warrant).
- Securities Issued:
- 2,030,314 shares of Common Stock.
- 5,421,250 Pre-Funded Warrants (exercisable at $0.0001/share).
- 7,451,564 Series Warrants (Series 1 and Series 2).
- Warrant Terms:
- Series 1: Exercise price $13.42; expires June 30, 2027.
- Series 2: Exercise price $20.13; expires December 31, 2030.
Financial Results: The filing references a press release containing preliminary financial information as of December 31, 2025. However, the text of this 8-K does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to Exhibit 99.1 for these figures.
Material Changes and Unusual Items
The primary material change is the dilution of existing shareholders due to the issuance of approximately 7.45 million shares of Common Stock (via direct issuance and Pre-Funded Warrants) and the creation of 7.45 million additional shares via Series Warrants. The offering includes a weighted-average price adjustment mechanism for the Series Warrants if the Company raises capital below $13.42 per share prior to June 30, 2027, with a floor of $6.71 per share.
Guidance, Outlook, and Risks
The Company intends to use the proceeds to fund its clinical development programs and general corporate purposes. The filing notes that the information regarding financial results and the investor presentation (Exhibit 99.2) is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act. No specific forward-looking guidance or risk factors beyond standard offering terms are detailed in the body of this report.
Key Facts for Investor Verification
- Verify the specific cash balance and burn rate in the preliminary financial data attached as Exhibit 99.1.
- Confirm the total fully diluted share count post-closing, accounting for the 2.03M shares, 5.42M Pre-Funded Warrants, and 7.45M Series Warrants.
- Review the "Weighted-Average Price" adjustment clause to understand potential future dilution if the stock price remains below $13.42.
- Check the closing date of the offering, expected to be January 13, 2026.